Super-Rehab: a Novel Approach to Treat Atrial Fibrillation

Prior treatment

• Prior AF ablation

Other illness

• Prognostic coronary artery disease, defined as left main stem \>50% stenosis and/or ≥ moderate disease in ≥3 major epicardial vessels requiring revascularisation.
• Unstable angina
• New York Heart Association class III/IV heart failure or severe left ventricular impairment
• Severe heart valve disease
• Severe hypertension (BP \>180/120mmHg) despite optimising anti-hypertensive therapy
• Uncontrolled arrhythmia or higher degree heart block
• History of aortic dissection
• Recent acute pulmonary embolus, deep vein thrombosis, stroke or transient ischaemic attack (\<6 months)
• Significant acute or chronic renal failure that would preclude contrast use at CT
• Significant pulmonary fibrosis or interstitial lung disease (as assessed by a pulmonary physician)
• A clinically significant ECG abnormality at the screening visit, which in the opinion of the investigators exposes the subject to risk by enrolling in the trial, including but not limited to: sustained ventricular tachycardia, high-grade atrioventricular block (second-degree Mobitz type II or third-degree heart block), evidence of acute ischemia (ST-segment elevation or depression \>1 mm), or other arrhythmias deemed clinically significant by the study cardiologist.

Other

• Significant cardiomyopathy (as assessed by Cardiologist, e.g. hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy)
• Severe autonomic or peripheral neuropathy
• Physically unable to participate in high-intensity exercise
• Pregnancy
• Participation in another intervention-based research study
• Inability to fully understand the instructions provided during the study

• Aged \>18
• Symptomatic AF (paroxysmal or persistent \<12-months) with a rhythm control management strategy selected including consideration of referral for a cardioversion or ablation forming part of their planned pathway
• BMI ≥27m/kg2